Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Ipsen is conducting a clinical study titled An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours. The study aims to determine the appropriate dosage, safety, and effectiveness of the new drug IPN01195 in adults with advanced solid tumors, which are cancers that have spread from their original site.
Intervention/Treatment: The study tests IPN01195, a new drug intended to treat advanced solid tumors. It is administered as a single agent to assess its safety and efficacy in affected adults.
Study Design: This interventional study uses a randomized allocation and a sequential intervention model. It is open-label, meaning there is no masking, and its primary purpose is treatment. The study is divided into two parts: dose escalation and randomization to determine the optimal dose.
Study Timeline: The study began on February 12, 2025, with the latest update submitted on August 27, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
Market Implications: This study could significantly impact Ipsen’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio in oncology. The competitive landscape in cancer treatment is fierce, and advancements in this area could position Ipsen favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.